CenterBook Partners’s PTC Therapeutics PTCT Stock Holding History

CenterBook Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Sell	37,795 -19,018	-33%	-$1.37M	0.15%	156
2026 Q1	$3.87M	Buy	+56,813	New	+$4.02M	0.21%	126
2023 Q3	–	Sell	-16,175	Closed	-$658K	–	484
2023 Q2	$658K	Buy	+16,175	New	+$791K	0.08%	303
2023 Q1	–	Sell	-11,131	Closed	-$425K	–	447
2022 Q4	$425K	Buy	+11,131	New	+$463K	0.07%	300
2022 Q3	–	Sell	-6,845	Closed	-$274K	–	433
2022 Q2	$274K	Sell	6,845 -5,076	-43%	-$178K	0.06%	334
2022 Q1	$445K	Buy	+11,921	New	+$459K	0.16%	224

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CenterBook Partners's PTCT Position: Q2 2026 in Review

CenterBook Partners reduced its PTC Therapeutics (PTCT) stake by 33% in Q2 2026, selling an estimated $1.37M and leaving 37,795 shares worth $3.08M. The position accounts for 0.15% of the portfolio, ranked #156.

CenterBook Partners first reported a position in PTCT in Q1 2022 and has held it in 6 quarters since. The position peaked at $3.87M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

CenterBook Partners held 37,795 shares of PTC Therapeutics worth $3.08M as of Q2 2026.
CenterBook Partners sold 19,018 PTC Therapeutics shares in Q2 2026, an estimated $1.37M.
PTC Therapeutics made up 0.15% of CenterBook Partners's portfolio in Q2 2026, its #156 holding.
CenterBook Partners first reported a position in PTC Therapeutics in Q1 2022 and has held it in 6 quarters since.
CenterBook Partners's PTC Therapeutics position peaked at $3.87M in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.